View More View Less
  • 1 Debreceni Egyetem, Általános Orvostudományi Kar, Debrecen, Nagyerdei krt. 98., 4032
  • 2 Szegedi Tudományegyetem, Általános Orvostudományi Kar, Szeged
  • 3 Pécsi Tudományegyetem, Általános Orvostudományi Kar, Pécs
  • 4 Debreceni Egyetem, Általános Orvostudományi Kar, Debrecen
  • 5 Semmelweis Egyetem, Általános Orvostudományi Kar, Budapest
Open access

Absztrakt:

A cardialis autonóm neuropathia (CAN) az 1-es és 2-es típusú diabetes mellitus gyakori szövődménye, melyet a cardiovascularis rendszer autonóm szabályozásának zavaraként definiálnak. A CAN szoros összefüggést mutat a halálozási adatokkal, és bizonyos vizsgálatok szerint a vascularis szövődmények, köztük a stroke, a koszorúér-betegség és a szívinfarktus okozta halálozással is. Korai stádiumban a CAN tünetmentes lehet, majd a betegség előrehaladtával megjelennek a klinikai tünetek is. A tünetmentes periódusban a cardiovascularis reflextesztek segítségével azonosítható, melyek prognosztikai értékkel is bírnak. A tünetek megjelenését követően az autonóm működési zavar a nyugalmi tachycardia, csökkent fizikai terhelhetőség, ortosztatikus hipotónia, syncope, intraoperatív cardiovascularis instabilitás, néma szívizominfarktus vagy ischaemia okozta megnövekedett halálozás alapján diagnosztizálható. Bár a CAN nagyon gyakori és előrehaladott esetekben súlyos diabeteses szövődmény, gyakran nem kerül felismerésre. Mivel a betegség korai stádiumában a cardiovascularis denerváció részlegesen visszafordítható, vagy progressziója lelassítható, a legújabb irányelvek határozottan ajánlják a CAN szűrését diabeteses betegekben. Az alábbiakban összefoglaljuk a diabeteses CAN szűrésére alkalmas diagnosztikai lehetőségeket. Orv Hetil. 2019; 160(35): 1366–1375.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018; 138: 271–281.

  • 2

    Sztanek F, Molnárné Molnár Á, Balogh Z. The role of oxidative stress in the development of diabetic neuropathy. [Az oxidatív stressz szerepe a diabeteses neuropathia kialakulásában.] Orv Hetil. 2016; 157: 1939–1946. [Hungarian]

  • 3

    Winkler G, Kempler P. Pathomechanism of diabetic neuropathy: background of the pathogenesis-oriented therapy. [A neuropathia diabetica patomechanizmusa: az oki kezelés elméleti háttere.] Orv Hetil. 2010; 151: 971–981. [Hungarian]

  • 4

    Várkonyi T, Körei A, Putz Z, et al. Advances in the management of diabetic neuropathy. Minerva Med. 2017; 108: 419–437.

  • 5

    Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care 2017; 40: 136–154.

  • 6

    Barkai L, Szabó L. Urinary bladder dysfunction in diabetic children with and without subclinical cardiovascular autonomic neuropathy. Eur J Pediatr. 1993; 152: 190–192.

  • 7

    Pittasch D, Lobmann R, Behrens-Baumann W, et al. Pupil signs of sympathetic autonomic neuropathy in patients with type 1 diabetes. Diabetes Care 2002; 25: 1545–1550.

  • 8

    Martin CL, Albers JW, Pop-Busui R, et al. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014; 37: 31–38.

  • 9

    Low PA, Benrud-Larson LM, Sletten DM, et al. Autonomic symptoms and diabetic neuropathy: a population-based study. Diabetes Care 2004; 27: 2942–2947.

  • 10

    Spallone V, Ziegler D, Freeman R, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev. 2011; 27: 639–653.

  • 11

    Ziegler D, Voss A, Rathmann W, et al. Increased prevalence of cardiac autonomic dysfunction at different degrees of glucose intolerance in the general population: the KORA S4 survey. Diabetologia 2015; 58: 1118–1128.

  • 12

    Kempler P, Tesfaye S, Chaturvedi N, et al. Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study. Diabet Med. 2002; 19: 900–909.

  • 13

    Pop-Busui R, Evans GW, Gerstein HC, et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010; 33: 1578–1584.

  • 14

    Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003; 348: 383–393.

  • 15

    Maser RE, Mitchell BD, Vinik AI, et al. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 2003; 26: 1895–1901.

  • 16

    Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33: 2285–2293.

  • 17

    Istenes I, Körei AE, Putz Z, et al. Heart rate variability is severely impaired among type 2 diabetic patients with hypertension. Diabetes Metab Res Rev. 2014; 30: 305–312.

  • 18

    Istenes I, Keresztes K, Tündik A, et al. Blood pressure response to standing in the diagnosis of autonomic neuropathy: are initial (supine) values of importance. Diabet Med. 2007; 24: 325–327.

  • 19

    Orosz A, Baczkó I, Nyiraty S, et al. Increased short-term beat-to-beat QT interval variability in patients with impaired glucose tolerance. Front Endocrinol. 2017; 8: 129.

  • 20

    Ewing DJ, Campbell IW, Burt AA, et al. Vascular reflexes in diabetic autonomic neuropathy. Lancet 1973; 302: 1354–1356.

  • 21

    Ewing DJ. Diabetic autonomic neuropathy and the heart. Diabetes Res Clin Pract. 1996; 30(Suppl) 31–36.

  • 22

    Ewing DJ, Campbell IW, Clarke BF. Assessment of cardiovascular effects in diabetic autonomic neuropathy and prognostic implications. Ann Intern Med. 1980; 92: 308–311.

  • 23

    Körei AE, Kempler M, Istenes I, et al. Why not to use the handgrip test in the assessment of cardiovascular autonomic neuropathy among patients with diabetes mellitus? Curr Vasc Pharmacol. 2017; 15: 66–73.

  • 24

    Fisher VL, Tahrani AA. Cardiac autonomic neuropathy in patients with diabetes mellitus: current perspectives. Diabetes Metab Syndr Obes. 2017; 10: 419–434.

  • 25

    Bernardi L, Spallone V, Stevens M, et al. Methods of investigation for cardiac autonomic dysfunction in human research studies. Diabetes Metab Res Rev. 2011; 27: 654–664.

  • 26

    Sammito S, Böckelmann I. New reference values of heart rate variability during ordinary daily activity. Heart Rhythm 2017; 14: 304–307.

  • 27

    Cha SA, Park YM, Yun JS, et al. Time- and frequency-domain measures of heart rate variability predict cardiovascular outcome in patients with type 2 diabetes. Diabetes Res Clin Pract. 2018; 143: 159–169.

  • 28

    Allman KC, Stevens MJ, Wieland DM, et al. Noninvasive assessment of cardiac diabetic neuropathy by carbon-11 hydroxyephedrine and positron emission tomography. J Am Coll Cardiol. 1993; 22: 1425–1432.

  • 29

    Mäntysaari M, Kuikka J, Mustonen J, et al. Noninvasive detection of cardiac sympathetic nervous dysfunction in diabetic patients using [123I]metaiodobenzylguanidine. Diabetes 1992; 41: 1069–1075.

  • 30

    Gerritsen J, Dekker JM, TenVoorde BJ, et al. Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease: the Hoorn Study. Diabetes Care 2001; 24: 1793–1798.

  • 31

    Balcioğlu S, Arslan U, Türkoğlu S, et al. Heart rate variability and heart rate turbulence in patients with type 2 diabetes mellitus with versus without cardiac autonomic neuropathy. Am J Cardiol. 2007; 100: 890–893.

  • 32

    Hilsted J. Catecholamines and diabetic autonomic neuropathy. Diabet Med. 1995; 12: 296–297.

  • 33

    Hoffman RP, Sinkey CA, Kienzle MG, et al. Muscle sympathetic nerve activity is reduced in IDDM before overt autonomic neuropathy. Diabetes 1993; 42: 375–380.

  • 34

    Papanas N, Boulton AJ, Malik RA, et al. A simple new non-invasive sweat indicator test for the diagnosis of diabetic neuropathy. Diabet Med. 2013; 30: 525–534.

  • 35

    He T, Wang C, Zuo A, et al. Electrochemical skin conductance may be used to screen for diabetic cardiac autonomic neuropathy in a Chinese population with diabetes. J Diabetes Res. 2017; 2017: 8289740.

  • 36

    Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998; 280: 1831–1836.

  • 37

    Spallone V, Morganti R, D’Amato C, et al. Validation of DN4 as a screening tool for neuropathic pain in painful diabetic polyneuropathy. Diabet Med. 2012; 29: 578–585.

  • 38

    Roy MK, Kuriakose AS, Varma SK, et al. A study on comparative efficacy and cost effectiveness of pregabalin and duloxetine used in diabetic neuropathic pain. Diabetes Metab Syndr. 2017; 11: 31–35.

  • 39

    Bouhassira D, Attal N, Alchaar H, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005; 114: 29–36.

  • 40

    Suarez GA, Opfer-Gehrking TL, Offord KP, et al. The Autonomic Symptom Profile: a new instrument to assess autonomic symptoms. Neurology 1999; 52: 523–528.

  • 41

    Low PA. Composite autonomic scoring scale for laboratory quantification of generalized autonomic failure. Mayo Clin Proc. 1993; 68: 748–752.

  • 42

    Sletten DM, Suarez GA, Low PA, et al. COMPASS 31: a refined and abbreviated Composite Autonomic Symptom Score. Mayo Clin Proc. 2012; 87: 1196–1201.

  • 43

    Treister R, O’Neil K, Downs HM, et al. Validation of the Composite Autonomic Symptom Scale 31 (COMPASS-31) in patients with and without small fiber polyneuropathy. Eur J Neurol. 2015; 22: 1124–1130.

  • 44

    Greco C, Di Gennaro F, D’Amato C, et al. Validation of the Composite Autonomic Symptom Score 31 (COMPASS 31) for the assessment of symptoms of autonomic neuropathy in people with diabetes. Diabet Med. 2017; 34: 834–838.

  • 45

    Rea NA, Campbell CL, Cortez MM. Quantitative assessment of autonomic symptom burden in postural tachycardia syndrome (POTS). J Neurol Sci. 2017; 377: 35–41.

  • 46

    Kim Y, Seok JM, Park J, et al. The composite autonomic symptom scale 31 is a useful screening tool for patients with parkinsonism. PLoS ONE 2017; 12: e0180744.

  • 47

    Mohammed J, Derom E, De Wandele I, et al. Autonomic symptoms in patients with moderate and severe chronic obstructive pulmonary disease. Acta Clin Belg. 2018; 73: 182–190.

  • 48

    Sander C, Hildebrandt H, Schlake HP, et al. Subjective cognitive fatigue and autonomic abnormalities in multiple sclerosis patients. Front Neurol. 2017; 8: 475.

  • 49

    Gaede P, Vedel P, Parving HH, et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617–622.

  • 50

    Vinik AI, Erbas T, Casellini CM. Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease. J Diabetes Investig. 2013; 4: 4–18.